

Correction: Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study

Manuel de la Torre-Aláez M, Matilla A, Varela M, *et al.* Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study. *Jr ImmunoTher Cancer* 2022;10:e005457. doi: 10.1136/jitc-2022-005457.

This article has been corrected since it was first published. A previous revision of the manuscript was published in error. Supplementary Table S2 is now incorporated in the main article as Table 3, and a new Figure S1 has been included in the supplementary material.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2023;11:e005457corr1. doi:10.1136/jitc-2022-005457corr1

